Cardiovascular Diabetology
Journal Abbreviation: CARDIOVASC DIABETOL
ISSN: 1475-2840
Publisher: BioMed Central
Publications (16)
Is GFR decline induced by SGLT2 inhibitor of clinical importance? (2024)
Günes-Altan M, Bosch A, Striepe K, Bramlage P, Schiffer M, Schmieder R, Kannenkeril D
Journal article
Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study (2023)
Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, Duffin KL, et al.
Journal article
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk (2022)
Boehm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, et al.
Journal article
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers (2022)
Geßner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm M, et al.
Journal article
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure (2021)
Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, et al.
Journal article
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021)
Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al.
Journal article
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial (2019)
Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder R
Journal article
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes (2018)
Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder R
Journal article
Individualised treatment targets in patients with type-2 diabetes and hypertension (2018)
Schmieder R, Tschoepe D, Koch C, Ouarrak T, Gitt AK
Journal article
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial (2018)
Karg M, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, et al.
Journal article